The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant …
The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant …
A joint venture has been set up by ATAI Life Sciences and DemeRX to develop a one and done treatment that will work to give people suffering from addiction a neurochemical reset of sorts using a drug derived from a Western African plant.
The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant and ...
Continue Reading →
Unlike methadone, a substitute and therefore also an opioid, ibogaine is often referred to as addiction interrupter that appears to reset the brain …
Michael D. Shaw is a biochemist and freelance writer. A graduate of the University of California, Los Angeles, and a protégé of the late Willard Libby, winner of the 1960 Nobel Prize in chemistry, Shaw also did postgraduate work at the Massachusetts Institute of Technology. Based in Virginia, he covers technology, health care and entrepreneurship, among other topics.
Astronauts sometimes face the gravest threats after they return to Earth. Facing depression, alcoholism and ...
North America has been ravaged by the opioid crisis with ...